Enveric Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Selling, General & Admin	6.45	8.85	11.73	19.88	5.32	Upgrade
Research & Development	2.84	7.25	7.91	4.76	0.17	Upgrade
Operating Expenses	9.63	16.45	19.96	25.29	5.62	Upgrade
Operating Income	-9.63	-16.45	-19.96	-25.29	-5.62	Upgrade
Interest Expense	-	-	-0.01	-0.01	-0.45	Upgrade
Interest & Investment Income	0	0	-	-	-	Upgrade
Other Non Operating Income (Expenses)	0.07	-0.82	7.46	8.2	-0.8	Upgrade
EBT Excluding Unusual Items	-9.57	-17.26	-12.5	-17.1	-6.86	Upgrade
Merger & Restructuring Charges	-	-	-	-0.65	-	Upgrade
Impairment of Goodwill	-	-	-1.49	-8.23	-	Upgrade
Asset Writedown	-	-	-5.97	-30.45	-	Upgrade
Pretax Income	-9.57	-17.26	-19.96	-56.43	-6.86	Upgrade
Income Tax Expense	0.01	0.03	-1.49	-7.45	-	Upgrade
Net Income	-9.57	-17.29	-18.47	-48.98	-6.86	Upgrade
Preferred Dividends & Other Adjustments	-	0.17	0.33	-	-	Upgrade
Net Income to Common	-9.57	-17.46	-18.8	-48.98	-6.86	Upgrade
Shares Outstanding (Basic)	1	0	0	0	-	Upgrade
Shares Outstanding (Diluted)	1	0	0	0	-	Upgrade
Shares Change (YoY)	249.39%	49.31%	206.13%	-	-	Upgrade
EPS (Basic)	-19.04	-121.29	-195.02	-1555.32	-	Upgrade
EPS (Diluted)	-19.04	-121.29	-195.02	-1555.32	-	Upgrade
Free Cash Flow	-7.73	-14.1	-17.73	-11.65	-3.89	Upgrade
Free Cash Flow Per Share	-15.36	-97.96	-183.93	-369.88	-	Upgrade
EBITDA	-9.29	-16.1	-19.63	-24.64	-5.5	Upgrade
D&A For EBITDA	0.34	0.34	0.33	0.66	0.12	Upgrade
EBIT	-9.63	-16.45	-19.96	-25.29	-5.62	Upgrade

Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q